A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

Clinical trial NCT07375524 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07375524
Sponsor: Shanghai Escugen Biotechnology Co., Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Sjögren Syndrome

Start date: 2026-03-01
Primary completion: 2027-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.